TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17696268
Drug: Computer tool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer tool designed to elicit preferences based on patient tradeoffs for treatment options.
Study: 11960953
Drug: ACh infusion
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACh infusion
Study: 11960953
Drug: Nitroprusside (NTP)
DrugBank: Nitroprusside (DB00325)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nitroprusside (NTP) infusion
Study: 9858440
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg once a day for 14 days
Study: 9858440
Drug: Piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piroxicam 20 mg once a day for 28 days
Study: 43255
Drug: Penbutolol (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (0.08 mg/kg i.v.)
Study: 43255
Drug: Alprenolol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (0.4 mg/kg i.v.)
Study: 43255
Drug: Propranolol (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (0.4 mg/kg i.v.)
Study: 43255
Drug: Propranolol (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (160 mg b.i.d. orally)
Study: 43255
Drug: Alprenolol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprenolol (400 mg b.i.d. orally)
Study: 43255
Drug: Penbutolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penbutolol (40 mg b.i.d. orally)
Study: 31481375
Drug: s-ketamine (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: s-ketamine (0.25 mg/kg bolus followed by 0.1 mg/kg/hour continuous infusion)
Study: 25679340
Drug: Real rTMS
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real rTMS (1 Hz, 15 min) followed by 45 min physical therapy
Study: 17705695
Drug: Pioglitazone (15-30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone (15-30 mg/day) as add-on therapy to metformin or SU
Study: 17705695
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of metformin (400 mg) and glibenclamide (2.5 mg)
Study: 11245756
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups performed 5 cycles of a 2‐second contraction with 22‐second rest periods between agonist muscle contractions.
Study: 10660974
Drug: Metoclopramide 10
Normalized name: metoclopramide 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoclopramide 10 mg t.i.d. (n = 14)
Study: 7887022
Drug: EcSf2a-2 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: EcSf2a-2 vaccine (4 doses, 4.1 x 10(8) to 1.1 x 10(9) c.f.u.)
Study: 18573718
Drug: 3.5 mM
Normalized name: Droplet Micron Pen Needles 34 g X 3.5 mm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.5 mM TauBr cream
Study: 18573718
Drug: 1% Clindamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% Clindamycin gel (Clindacin T)
Study: 10731011
Drug: NaHCO3 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaHCO3 (0.3 g x kg(‐1))
Study: 10731011
Drug: NaCl (0.21
Approvals — FDA: no, EMA: no, PMDA: no
Description: NaCl (0.21 g x kg(‐1))
Study: 1382132
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three antihistamines (Cetirizine, Promethazine, Chlorpheniramine)
Study: 3515919
Drug: Flurbiprofen (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (50 mg orally twice a day)
Study: 3515919
Drug: Sulindac (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac (150 mg orally twice a day)
Study: 29915914
Drug: Control (non-users
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (non-users of aspirin)
Study: 26663880
Drug: Clopidogrel (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600 mg, then 150 mg d(-1)) plus Aspirin (100 mg d(-1))
Study: 26663880
Drug: Ticagrelor (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180 mg) plus Aspirin (300 mg)
Study: 26663880
Drug: Ticagrelor plus
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor plus Aspirin
Study: 15942159
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran supplement (2 oat bran-enriched muffins per day, 28 g/day of oat bran)
Study: 15942159
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran supplement
Study: 10464004
Drug: Transdermal glyceryl‐trinitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl‐trinitrate (24 h/day)
Study: 10464004
Drug: Transdermal glyceryl‐trinitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal glyceryl‐trinitrate (16 h/day)
Study: 7628025
Drug: Rectal thiopentone
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal thiopentone 35 mg.kg‐1
Study: 2127268
Drug: Cefpodoxime proxetil,
Normalized name: Cefpodoxime Proxetil, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpodoxime proxetil, 5-day treatment
Study: 2127268
Drug: Penicillin, 10-day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin, 10-day treatment
Study: 26275480
Drug: PPV23 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV23 vaccine
Study: 21844413
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment for acute rhinosinusitis
Study: 19828373
Drug: Fatigue at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fatigue at the end of treatment as a predictive variable for persistent fatigue
Study: 16768837
Drug: Fructo-oligosaccharides (FOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fructo-oligosaccharides (FOS) 25-30 g/d
Study: 11642626
Drug: Hib conjugate
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hib conjugate vaccines (HbOC or Hib-OMP)
Study: 11642626
Drug: Pneumococcal polysaccharide
Normalized name: pneumococcal polysaccharides (23)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal polysaccharide vaccine (PnPs)
Study: 9539303
Drug: Cabergoline (CAB)
Normalized name: Cabergoline
DrugBank: Cabergoline (DB00248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cabergoline (CAB) at a dose of 0.5-1.5 mg/week (n = 7)
Study: 9539303
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BRC) at a dose of 5-15 mg/day (n = 10)
Study: 2816802
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg zinc (gluconate)
Study: 19015347
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg of body weight weekly (arm A)
Study: 19015347
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg loading dose followed by 6 mg/kg every 2 weeks (arm B)
Study: 19015347
Drug: 25 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/kg every 2 weeks for five doses (arm C)
Study: 9423751
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride 200 mg/day
Study: 9423751
Drug: Raloxifene hydrochloride
Normalized name: Raloxifene Hydrochloride
DrugBank: Raloxifene (DB00481)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Raloxifene hydrochloride 600 mg/day
Study: 9423751
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (Premarin 0.625 mg/day)
Study: 8423538
Drug: Triazolam (0.1‐0.32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triazolam (0.1‐0.32 mg/70 kg)
Study: 8423538
Drug: d‐Amphetamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: d‐Amphetamine (5 and 20 mg/70 kg)
Study: 28368869
Drug: Eye Movement
Normalized name: JOINT MOVEMENT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy administered in 12 one-hour sessions over a 1-month period.
Study: 19262229
Drug: Nicorandil (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil (15 mg/day)
Study: 18295282
Drug: Buccal mucosa
Normalized name: Diazepam 5 MG Buccal mucosa Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buccal mucosa grafts
Study: 18295282
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Buccal mucosa and Acellular bladder matrix)
Study: 10817717
Drug: Oral dOTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dOTC (800 mg)
Study: 10817717
Drug: Intravenous dOTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dOTC (100 mg)
Study: 8751401
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (RT) consisting of intracavitary brachytherapy alone to a median dose of 21 Gy for 17 patients.
Study: 8751401
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (RT) consisting of external beam RT to a median dose of 45 Gy followed by intracavitary brachytherapy to a median dose of 12 Gy for 81 patients.
Study: 6137427
Drug: Solpadeine (paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solpadeine (paracetamol 500 mg, codeine phosphate 8 mg, caffeine 30 mg)
Study: 6137427
Drug: Soluble DNP
Normalized name: DNP-VACC
DrugBank: Autologous DNP-conjugated tumour vaccine (DB17361)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble DNP (dextropropoxyphene napsylate equivalent to 32.5 mg hydrochloride and paracetamol 325 mg)
Study: 30858609
Drug: 4400 IU
Normalized name: Ascorbic Acid/Biotin/Calcium/Calcium Pantothenate/Chloride/Chromium/Copper/Cyanocobalamin/Folic Acid/Iodine/Iron/Magnesium/Manganese/Molybdenum/Niacinamide/Phosphorus/Phytonadione/Potassium/Pyridoxine/Riboflavin/Selenium/Thiamine/Vitamin A/Vitamin D/Vitamin E/Zinc 120 MG-0.015 MG-40 MG-10 MG-6.8 MG-0.015 MG-2 MG-0.009 MG-0.4 MG-0.15 MG-27 MG-100 MG-5 MG-0.015 MG-30 MG-31 MG-0.028 MG-7.5 MG-3 MG-3.4 MG-0.01 MG-3 MG-4400 IU-400 IU-30 IU-15 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4400 IU vitamin D daily
Study: 30858609
Drug: 400 IU
Normalized name: Vitamin D 400 IU Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 IU vitamin D daily (Control)
Study: 29774628
Drug: brexpiprazole 2
Normalized name: brexpiprazole 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 2 mg
Study: 29774628
Drug: brexpiprazole 4
Normalized name: brexpiprazole 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 4 mg
Study: 26301771
Drug: brexpiprazole 1
Normalized name: brexpiprazole 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: brexpiprazole 1 mg
Study: 24457632
Drug: 3-drug therapy
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3-drug therapy (N = 14)
Study: 24457632
Drug: 5-drug therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-drug therapy (N = 26)
Study: 20595280
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (weekly attention-control phone calls)
Study: 11491010
Drug: albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: albendazole 400 mg with ivermectin 200 micrograms/kg
Study: 11491010
Drug: albendazole 400
Normalized name: albendazole 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: albendazole 400 mg with diethylcarbamazine citrate (DEC) 6 mg/kg
Study: 11491010
Drug: albendazole 600
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: albendazole 600 mg with ivermectin 400 micrograms/kg
Study: 8319375
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (0.018 U/kg/day for 1 month followed by 0.036 U/kg/day for 1 month)
Study: 3520133
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg BAYo1248 administered prior to breakfast
Study: 3520133
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg BAYm1099 administered prior to breakfast, lunch, and dinner
Study: 30504569
Drug: Gabapentin (2400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (2400 mg/d, tid) + pulsed radiofrequency lesioning of the dorsal root ganglion
Study: 30504569
Drug: Oral gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral gabapentin (2400 mg/d, tid)
Study: 27240921
Drug: Oral L-tryptophan
Normalized name: L-TRYPTOPHAN
DrugBank: Tryptophan (DB00150)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral L-tryptophan (30, 60 or 120 mg/kg body weight)
Study: 25630245
Drug: Antagonist passive
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist passive static stretching (AS) for 40 seconds applied to pectoralis major prior to each set of seated row (SR)
Study: 25630245
Drug: Antagonist passive
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Antagonist passive static stretching (AS)
Study: 20619837
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of atorvastatin and fenofibrate
Study: 18199184
Drug: Solution-focused group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution-focused group therapy (SFGT)
Study: 18199184
Drug: Traditional problem-focused
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional problem-focused treatment
Study: 16523206
Drug: EFA‐supplemented test‐treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: EFA‐supplemented test‐treatment formula
Study: 8646820
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of midazolam (2 mg)
Study: 8646820
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of midazolam (1 mg)
Study: 22434523
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (daily calcium 1 g and vitamin D(3) 800 IU, plus additional oral 16,000 IU every 2 weeks if baseline 25(OH)D <30 ng/ml)
Study: 21245499
Drug: CC extension
Normalized name: EXTENSION TUBES
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC extension
Study: 21245499
Drug: CC flexion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC flexion
Study: 21245499
Drug: Extensor to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extensor to flexor strength ratio at CC axis
Study: 1460158
Drug: Integrated systemic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Integrated systemic therapy (IST)
Study: 6425033
Drug: One nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: One nitroglycerin plaster (5 mg liberation within 24 hours)
Study: 6425033
Drug: Two nitroglycerin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two nitroglycerin plasters (5 mg liberation within 24 hours)
Study: 6425033
Drug: Four nitroglycerin
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four nitroglycerin plasters (5 mg liberation within 24 hours)
Study: 6425033
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg 5‐isosorbide mononitrate (ISMN)
Study: 27941179
Drug: Safflower oil
Normalized name: Safflower Oil
DrugBank: Safflower oil (DB09446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil treatment for three months
Study: 21166343
Drug: Fluoxetine hydrochloride
Normalized name: Fluoxetine Hydrochloride
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine hydrochloride for 3 months
Study: 12503837
Drug: Olanzapine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (5 mg/day titrated to 20 mg/day)
Study: 24006861
Drug: Topical ocular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ocular hypotensive medication for 12 weeks
Study: 9607529
Drug: Intravenous cephazolin
Normalized name: Cephazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cephazolin 1 g every 6 h and gentamicin 80 mg every 8 h for 7 days
Study: 9607529
Drug: No antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antibiotics until the appearance of infective complications
Study: 7530585
Drug: Nevirapine 200
Normalized name: nevirapine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nevirapine 200 mg/day in combination with zidovudine 200 mg q8h
Study: 7530585
Drug: Nevirapine at
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine at doses of 12.5, 50, and 200 mg/day
Study: 7530585
Drug: Nevirapine alone
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nevirapine alone or in combination with zidovudine
Study: 2223677
Drug: Prophylactic oral
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic oral salbutamol (74 women)
Study: 23829508
Drug: HM30181 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 at doses ≥10 mg
Study: 23829508
Drug: HM30181 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HM30181 (1, 5, 10, 15 mg)
Study: 15655271
Drug: Continuous simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous simvastatin 10 mg/day for four months
Study: 15655271
Drug: Intermittent simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent simvastatin 20 mg three times a week for four months
Study: 10754624
Drug: Fentanyl concentration
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl concentration of 0.72 +/- 0.07 ng/ml
Study: 10754624
Drug: Fentanyl concentration
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl concentration of 0.94 +/- 0.06 ng/ml
Study: 1845927
Drug: Medical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical therapy for primary sclerosing cholangitis
Study: 30022574
Drug: Drug Monograph
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug Monograph
Study: 28475268
Drug: Regimen A
Normalized name: CHLOROXYLENOL 5 g in 1000 mL TOPICAL SOAP [REGIMEN ANTIMICROBIAL]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimen A (standard treatment)
Study: 27281811
Drug: PRO+EX (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO+EX (40 g protein with evening physical activity)
Study: 27281811
Drug: PRO (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO (40 g protein without evening physical activity)
Study: 31996267
Drug: Ojeok-san plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ojeok-san plus Saengmaek-san (5.76 g, three times per day for 6 weeks)
Study: 28105731
Drug: liraglutide (1.8 mg/d)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: liraglutide (1.8 mg/d)
Study: 25770176
Drug: Oral ergocalciferol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ergocalciferol, 50,000 IU weekly (n=36)
Study: 25770176
Drug: Oral ergocalciferol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ergocalciferol, 50,000 IU monthly (n=33)
Study: 25770176
Drug: Oral ergocalciferol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ergocalciferol, 50,000 IU weekly
Study: 25770176
Drug: Oral ergocalciferol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ergocalciferol, 50,000 IU monthly
Study: 15955039
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch (EBP) performed on day 2
Study: 15955039
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch (EBP) performed on day 3
Study: 15955039
Drug: Epidural blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural blood patch (EBP) performed on day 4
Study: 12601664
Drug: Routine therapy-motor
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine therapy-motor training for upper-limb use and upper-limb stretches (5 days a week).
Study: 9447855
Drug: Aprotinin (1.106
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aprotinin (1.106 KIU bolus followed by 5 x 10(5) KIU/h infusion)
Study: 31957965
Drug: Extended dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended dual antiplatelet therapy (DAPT) beyond 12 months
Study: 26492058
Drug: Intraoperative Steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative Steroid Administration
Study: 22665903
Drug: Vandetanib 300
Normalized name: vandetanib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vandetanib 300 mg/d orally
Study: 19650804
Drug: Ropivacaine 13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 13 mg
Study: 19650804
Drug: Ropivacaine 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 10 mg plus sufentanil 5 microg
Study: 19095139
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (target LDL-C <= 100 mg/dl)
Study: 12032392
Drug: loading dose
Normalized name: NUZYRA 7-Day Oral Pack including loading dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: loading dose clopidogrel (450 mg)
Study: 12032392
Drug: aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin + ticlopidine post-stenting
Study: 12032392
Drug: aspirin +
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin + abciximab + ticlopidine post-stenting
Study: 10073848
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (no revascularization)
Study: 7888514
Drug: Thiopentone (4-6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4-6 mg.kg‐1)
Study: 7888514
Drug: Propofol (2-2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2-2.5 mg.kg‐1)